Company: MiMedx Group, Inc.
Kaskela Law LLC is investigating MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”) on behalf of the Company’s stockholders.
On June 7, 2018, MiMedx disclosed that “the Audit Committee of the Company’s Board of Directors, with concurrence from management of the Company, has concluded that the Company’s previously issued consolidated financial statements relating to each of the fiscal years ended December 31, 2012, 2013, 2014, 2015, and 2016 and each of the interim periods ended March 31, June 30 and September 30, 2017 should be restated. As a result, all communications and financial information with respect to the fourth quarter of 2017 and the first quarter of 2018 should no longer be relied upon, and the Company is withdrawing all prior financial guidance issued for 2018.”
Additionally, MiMedx disclosed that “Edward J. Borkowski has been appointed the Company’s Interim Chief Financial Officer, effective immediately. The appointment of Mr. Borkowski follows Michael J. Senken’s departure as the Company’s Chief Financial Officer effective June 6, 2018. The Company also announced that John E. Cranston has left his role as Vice President, Corporate Controller and Treasurer, effective June 6, 2018.”
Following this news, shares of the Company’s common stock significantly declined on June 7, 2018.
MiMedx stockholders are encouraged to contact Kaskela Law LLC to discuss their legal rights and options with respect to this investigation, or to complete the information form on this page.